308110-07-8

Basic information

• Product Name: 6-Hydroxy-2-Methyl-3,4-dihydroisoquinolin-1(2H)-one
• Synonyms: 6-Hydroxy-2-Methyl-3,4-dihydroisoquinolin-1(2H)-one;3,4-dihydro-6-hydroxy-2-methyl-1(2H)-Isoquinolinone
• CAS NO: 308110-07-8
• Molecular Formula: C₁₀H₁₁NO₂
• Molecular Weight: 177.19984
• Mol File: 308110-07-8.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 6-Hydroxy-2-Methyl-3,4-dihydroisoquinolin-1(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Hydroxy-2-Methyl-3,4-dihydroisoquinolin-1(2H)-one(308110-07-8)
• EPA Substance Registry System: 6-Hydroxy-2-Methyl-3,4-dihydroisoquinolin-1(2H)-one(308110-07-8)

Safety Data

• Hazardous Substances Data: 308110-07-8(Hazardous Substances Data)

Usage

General Description

6-Hydroxy-2-methyl-3,4-dihydroisoquinolin-1(2H)-one is a chemical compound with a structure containing a dihydroisoquinolinone ring system with a hydroxyl group and a methyl group attached to it. It has potential therapeutic applications as it has shown to possess antioxidant, anti-inflammatory, and neuroprotective properties. 6-Hydroxy-2-Methyl-3,4-dihydroisoquinolin-1(2H)-one has also been studied for its potential use in the treatment of neurodegenerative diseases and as an anticancer agent. Additionally, it may have use in the development of new pharmaceutical drugs and as a research tool in the study of various biological processes. However, further research is needed to fully understand its potential applications and mechanisms of action in various biological systems.

Upstream product

• 35714-27-3 6-methoxy-2-methyl-3,4-dihydro-1(2H)-isoquinolinone 
• 2039-67-0 2-(3-methoxyphenyl)-1-ethanamine 
• 22246-12-4 6-methoxy-1,2,3,4-tetrahydro-1-oxoisoquinoline 
• 33543-63-4 ethyl-N-<2-(3-methoxyphenyl)ethyl>-carbamate 

Downstream Products

• 308110-09-0 6-[hydroxy(phenyl)methyl]-2-methyl-3,4-dihydro-1(2H)-isoquinolinone 

Relevant articles and documents

FLUOROALLYLAMINE DERIVATIVE AND USE THEREOF

The present invention relates to a fluoroallylamine derivative and use thereof. In particular, the present invention relates to a compound as shown in Formula I, a prodrug, an isomer, an isotope-labeled compound, a solvate or a pharmaceutically acceptable salt thereof, which has VAP-1/SSAO inhibitory activity, and can be used for treating a disease associated with VAP-1/SSAO overactivity.

AMINE COMPOUND FOR INHIBITING SSAO / VAP-1 AND USE THEREOF

An amine compound serving as a semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, and an application thereof in medicines that can be used for treating inflammation and/or inflammation related diseases, diabetes and/or a disease related diabetes, psychiatric disorder, ischemic disease, vascular disease, fibrosis, or tissue transplant rejection.

New diarylmethylpiperazines as potent and selective nonpeptidic δ opioid receptor agonists with increased in vitro metabolic stability

Nonpeptide δ opioid agonists are analgesics with a potentially improved side-effect and abuse liability profile, compared to classical opioids. Andrews analysis of the NIH nonpeptide lead SNC-80 suggested the removal of substituents not predicted to contribute to binding. This approach led to a simplified lead, N,N-diethyl-4-[phenyl(1-piperazinyl)methyl]benzamide (1), which retained potent binding affinity and selectivity to the human δ receptor (IC50 = 11 nM, μ/δ = 740, κ/δ > 900) and potency as a full agonist (EC50 = 36 nM) but had a markedly reduced molecular weight, only one chiral center, and increased in vitro metabolic stability. From this lead, the key pharmacophore groups for δ receptor affinity and activation were more clearly defined by SAR and mutagenesis studies. Further structural modifications on the basis of 1 confirmed the importance of the N,N-diethylbenzamide group and the piperazine lower basic nitrogen for δ binding, in agreement with mutagenesis data. A number of piperazine N-alkyl substituents were tolerated. In contrast, modifications of the phenyl group led to the discovery of a series of diarylmethylpiperazines exemplified by N,N-diethyl-4-[1-piperazinyl(8-quinolinyl)-methyl]benzamide (56) which had an improved in vitro binding profile (IC50 = 0.5 nM, μ/δ = 1239, EC50 = 3.6 nM) and increased in vitro metabolic stability compared to SNC-80.